Acmic

Quick links to important sections

Acmic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acmic

What is Acmic? Essential B-Complex Overview

Property Description
Active Ingredients Calcium D-pantothenate, Folic Acid, Mecobalamin, Niacinamide, Thiamine, Pyridoxine
Form Oral Solid Dosage Form (Tablet)
Pharmacological Class B-Complex Vitamin Supplement
Common Use Systemic Nutritional Support; Deficiency Prevention
Origin Synthetic and Semi-Synthetic Derivatives

Acmic is a poly-component essential micronutrient formulation classified within the pharmacological class of B-complex vitamin supplements, designed for systemic nutritional support. This oral solid dosage form is a combination product that delivers a blend of six essential water-soluble B-vitamins in one tablet. Its structure and typical positioning suggest it is often available as an Over-The-Counter (OTC) supplement, making it readily accessible for generalized adult nutritional support.


What Type of Medicine is Acmic? (Identity and Classification)

Acmic functions primarily as a substrate replacement agent aimed at correcting underlying nutritional deficits, reflecting the necessity of these micronutrients for cellular metabolism. Its identity as a B-complex vitamin supplement is rooted in the essential, interdependent nature of its components. This specific combination, including the active coenzyme form Mecobalamin (Vitamin B12) rather than Cyanocobalamin, represents a differentiating feature often preferred for enhanced bioavailability. This formulation is recognized for providing broad nutritional coverage, distinguishing it from single-entity vitamin products. B-vitamins are essential coenzymes critical for the proper metabolism of fats, carbohydrates, and proteins.


Acmic Composition and General Purpose

The active core of Acmic is composed of six water-soluble vitamins: Thiamine (B1), Pyridoxine (B6), Niacinamide (B3), Calcium D-pantothenate (B5), Folic Acid (B9), and Mecobalamin (B12). These are synthetic or semi-synthetic derivatives that the body requires externally. The general purpose of Acmic is to address or prevent nutritional deficiencies, supporting overall metabolic efficiency. The inclusion of Folic Acid and B12 is fundamentally linked to the body's red blood cell synthesis, offering a typical use scenario that supports hematological health and helps maintain energy levels.

Regulatory References

  1. MedlinePlus Information on Vitamin B12

What side effects are possible with Acmic?

Possible Side Effects and Safety Information

The official safety profile for Acmic, a B-complex vitamin supplement, is structured according to regulatory standards, classifying possible effects by frequency and system-organ class. The adverse reactions are primarily related to the oral intake of water-soluble vitamins.


Adverse Reaction Scope

Category Regulatory Description
Common Reactions Include Gastrointestinal Disorders (such as nausea, vomiting, or diarrhea) and Skin and Subcutaneous Tissue Disorders (such as flushing and rash). Flushing, specifically associated with Niacinamide, is documented to be more common at the initiation of treatment or following dose increases.
Serious Adverse Reactions Regulatory documentation highlights a rare risk of Anaphylactic Reaction (severe systemic hypersensitivity). The serious adverse reaction of Peripheral Sensory Neuropathy is explicitly associated with prolonged, high-dose exposure to the Pyridoxine (B6) component.
System-Organ Classes Adverse reactions are grouped across the Gastrointestinal, Nervous System, and Immune System categories as defined in regulatory texts.

Official Safety Constraints

Official labels define specific safety constraints. A known Hypersensitivity to any component is a regulatory contraindication. Constraints also exist related to pre-existing conditions, where caution is noted for individuals with Severe Hepatic Impairment or Active Peptic Ulcer Disease due to the Niacinamide component. Furthermore, the Folic Acid component carries an explicit note that it may mask the hematological signs of an underlying Mecobalamin (B12) deficiency.

Overdose and Emergency Response

Acmic Overdose and When to Seek Help

The official overdose profile for Acmic, a B-complex supplement, is defined by the toxicological effects of its high-concentration components, primarily Pyridoxine (Vitamin B6) and Niacinamide (Vitamin B3), as documented in regulatory sources.

Documented Overdose Manifestations

Overdose primarily presents with neurological and systemic disturbances. Officially documented signs of Pyridoxine toxicity include peripheral sensory neuropathy, resulting in symptoms like paresthesias (numbness or tingling) and motor impairment such as ataxia (loss of coordination). Niacinamide toxicity can lead to systemic effects, including severe flushing, headache, nausea, and vomiting.

Serious Outcomes and Immediate Actions

Severe overdose carries a risk of serious outcomes, including hepatotoxicity (liver damage), which may be confirmed by clinical signs like jaundice or laboratory findings of elevated hepatic transaminases. The Niacinamide component also carries a risk of severe hypotension in acute cases. If a suspected overdose occurs, or if severe symptoms such as difficulty walking, signs of nerve damage, or persistent vomiting are present, regulatory guidance mandates that the patient seek immediate medical attention.

Management and Constraints

Treatment for Acmic overdose is strictly symptomatic and supportive care. Official regulatory documentation confirms that no specific antidote is known for Pyridoxine toxicity. Management involves immediate cessation of the product. Population-specific considerations note an increased risk of myopathy in elderly patients and those with renal failure, associated with high-dose Niacinamide.

Therapeutic Uses of Acmic

What Oxytocin Treats: Main Uses and Benefits

The primary therapeutic domain of Oxytocin is in managing conditions characterized by periods of heightened symptoms related to labor and delivery, and in associated obstetric scenarios. Its core action is commonly used to help with uterine contractions. This agent is applied in addressing situations where the symptoms linked to organ-specific functional stress, such as inadequate uterine contractions, may affect the routine delivery process. The primary therapeutic domains include managing symptoms associated with conditions characterized by periods of heightened symptoms that necessitate labor induction, labor augmentation, or the need for supportive symptom management of postpartum bleeding.

This agent may assist with the induction of labor when medically necessary, and it plays a role in managing symptoms related to physical discomfort and hemorrhage postpartum. This action is considered relevant for easing postpartum bleeding and may assist with the process of placental separation. Overall, its use in these clinical settings that involve acute or unstable symptom patterns contributes to easing the overall symptom load during critical phases. “It provides support that helps ease the overall symptom burden.”


Quick Fact: Relief for Symptoms related to physical discomfort


Eligibility and Restrictions for Use

Official Regulatory Eligibility for Acmic

Populations for Whom Use is Contraindicated

Use of Acmic is formally contraindicated for any individual with a known hypersensitivity or allergy to any component of the formulation, as stated in regulatory labeling. The medicine is also prohibited for patients with Leber's Disease (Hereditary Optic Nerve Atrophy) due to the Mecobalamin component. A primary regulatory restriction dictates that use is contraindicated in cases of undiagnosed anemia (pernicious anemia), as the Folic Acid component may mask the progression of a B12 deficiency.


Conditional Use and Age-Group Rules

Eligibility Status Population/Condition
Established Use Adults and Children four years of age and older.
Use Not Established Infants and Children under four years of age.
Restricted Use Patients with impaired renal or hepatic function.

The official profile specifies that use during pregnancy and lactation is permitted but requires professional consultation to ensure that the higher, specific nutrient requirements are met. The profile also mandates restricted use in patients with certain comorbidities, such as those with a history of certain cancers or recent angioplasty.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Acmic's B-Complex components, based on authoritative government regulatory sources.

Drug-Drug Interaction Profile

Acmic Component Interacting Agent Official Regulatory Description
Pyridoxine (B6) Levodopa Officially noted to antagonize therapeutic effects when Levodopa is administered without a peripheral decarboxylase inhibitor.
Folic Acid (B9) Anticonvulsants (e.g., Phenytoin) Officially noted to antagonize anticonvulsant activity, which may necessitate dose adjustments of the anticonvulsant.
Mecobalamin (B12) Metformin Officially reduces serum B12 concentration, possibly due to interference with B12 absorption.

Interaction Constraints and Monitoring

Regulatory documents define specific procedural constraints for co-administration. The interaction between Mecobalamin (B12) and Metformin officially necessitates annual monitoring of hematologic parameters and periodic measurement of serum B12 concentrations. This monitoring is required due to the documented risk of reduced B12 exposure. Alcohol consumption is officially documented to decrease the gastrointestinal absorption of Thiamine (B1) and Pyridoxine (B6), and can contribute to Folic Acid (B9) deficiency. No mandatory administration separation windows (e.g., 'administer X hours apart') are explicitly documented in official labeling.

Mechanism of Action

Acmic is a formulation containing Methylcobalamin, the biologically active coenzyme form of vitamin B12. Its pharmacodynamic mechanism is centered on its function as a cofactor in fundamental metabolic pathways, particularly within neural and hematopoietic tissues.


Modulating One-Carbon Metabolism

Methylcobalamin is a necessary coenzyme for the enzyme methionine synthase (MTR). This interaction catalyzes the remethylation of homocysteine to methionine within the one-carbon metabolic pathway. This crucial biochemical step is mandatory for synthesizing S-adenosylmethionine (SAMe) and is integral to the generation of purines and pyrimidines required for DNA synthesis and subsequent cell division, including that of red blood cell precursors.


Influencing Myelin and Neural Structure

The production of SAMe, a downstream output of the methionine pathway, is required for specific methylation reactions within the nervous system. These reactions include the synthesis of phospholipids and proteins essential for the maintenance and formation of the myelin sheath surrounding axons. This activity contributes to the stable modulation of nerve signal transduction and influences processes associated with maintaining neural structural integrity at the cellular level.

Dosage and Administration Information

How to Use Acmic: Administration Guidelines

This section outlines the administration and dosing instructions for Acmic as established in standardized prescribing information. Acmic is an injectable medication requiring administration by a healthcare professional using sterile, aseptic technique.


Administration Scope

Parameter Instruction
Route of Administration Intramuscular (IM) Injection or Intravenous (IV) Infusion, depending on the specific product formulation and strength.
Dosing Schedule Therapy typically consists of an initial intensive phase (e.g., 500 micrograms (mcg) per dose daily) followed by a long-term maintenance phase (e.g., 1000 mcg monthly or quarterly).
Preparation Requirements Before use, the solution must be visually inspected for any particulate matter or discoloration. Undiluted administration is typical for IM injection; IV use may require specific dilution as noted in the product documentation.
Age-Group Rules Dosage for pediatric patients must be calculated according to body weight or specific age-group parameters defined in the prescribing information. The standard adult dose is typically used for the elderly unless otherwise specified.
Missed-Dose Rules If a scheduled dose is missed, it should be administered as soon as remembered. Do not administer two doses at once to compensate for the missed dose.

Procedural Structure

Step sequence for administration:

  • The healthcare provider must confirm the correct Acmic strength and dosage form is selected.
  • The solution is visually inspected for quality before drawing up the required dose using sterile equipment.
  • The dose is administered via the approved route (IM or IV) using strict aseptic technique to prevent contamination.
  • Injection sites must be rotated when the intramuscular route is used for repeated doses.

These instructions define the standardized procedural steps and dose frequency required for the proper administration of Acmic, ensuring consistent use within the recommended guidelines.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides an overview of the research studies that explored whether this drug may be relevant for pain and inflammation management. This information is purely descriptive of the research conducted and does not offer medical advice or suggest treatment suitability.

Monotherapy Studies

  • Chronic Pain Management: Studies evaluated measures of quality of life in participants with chronic pain. Research tracked changes in pain levels over time. Follow-up research is ongoing to further evaluate the long-term outcomes examined in early-phase trials.
  • Osteoarthritis: Research examined the study measurements related to chronic back pain and osteoarthritis. A Phase II trial evaluated measurements for individuals with mild to moderate arthritis in groups receiving the study drug. Further investigation is needed, as findings from the initial research were not conclusive, and larger-scale trials are being prepared to clarify the initial results.

Combination Therapy Trials

Research examined the drug’s potential role when used in combination with established non-pharmacological treatments.

  • With Physical Therapy: One study on combination therapy examined pain measurements in participants receiving the drug and standard physical therapy. The research compared the effect of drug X and Y combination versus monotherapy on mobility. The research did not draw a definitive conclusion regarding comparative outcomes.
  • Pharmacokinetics Research: Research investigated study metrics related to markers of inflammation over a defined timeframe. Studies collected data on drug pharmacokinetics following different methods of dosing. It is not yet clear what the optimal delivery method is.

Safety and Patient Populations

Research tracked the frequency of adverse events across various study groups.

  • Specific Conditions: Studies included information on treatment in participants with certain liver conditions. Additional research investigated potential changes in kidney function and blood pressure observed in subsets of study participants.
  • Adverse Event Monitoring: A registry study is currently tracking the incidence and frequency of common adverse events over a 12-month period. The collected data on adverse events indicated a limited frequency of serious reported adverse occurrences, but long-term data is pending final analysis.

Key Studies & References

  1. A randomized, controlled trial of Acmic monotherapy for chronic pain management in osteoarthritis: Phase III study data

Frequently Asked Questions (FAQ)

Common questions about Acmic (FAQ)

Q: Do studies suggest Acmic is effective for its intended use?

Acmic is classified as a B-complex vitamin supplement intended for systemic nutritional support and deficiency prevention. Official information from regulatory bodies and nutritional research confirms that B vitamins are necessary coenzymes, essential for key metabolic processes like cell function and DNA synthesis. The established physiological role of these vitamins forms the basis for its use.

Q: Is it okay to take Acmic with common pain relievers like Tylenol or Advil?

Official drug interaction information for Acmic’s B-complex components typically does not list interactions with common, non-prescription pain relievers such as acetaminophen (Tylenol) or ibuprofen (Advil). However, regulatory guidance recommends discussing the use of all products with a healthcare professional.

Q: Can people with [broad chronic condition, e.g., 'high blood pressure'] use Acmic?

Regulatory documents list specific contraindications (conditions where the drug must not be used) and restrictions, such as Leber's Disease and Severe Hepatic Impairment. Since common chronic conditions like high blood pressure are generally not listed as specific contraindications for B-complex supplements, official documents do not typically include high blood pressure as a specific contraindication.

Q: Why do people sometimes say Acmic makes them feel [vague side effect, e.g., 'dizzy']?

While specific symptoms like 'dizziness' may not be listed as a common side effect in official Acmic labeling, adverse event monitoring sometimes notes such symptoms under Postmarketing Experience. It is also recognized that a severe systemic hypersensitivity, known as anaphylaxis, can cause symptoms that might include lightheadedness or confusion, which is listed as a serious adverse event in regulatory documents.

Q: Does Acmic affect mood or sleep patterns?

Adverse reaction reporting for Acmic and similar B-complex supplements includes the Nervous System as a potential system-organ class for effects. However, specific changes to mood or sleep patterns are generally not listed as common or serious adverse reactions in the official safety profile.

Q: Is Acmic known to interact with caffeine?

Official regulatory documents typically do not list an interaction between Acmic's B-complex components and caffeine. No explicit caution regarding the consumption of caffeine is generally provided in the drug interaction information.

Q: What does 'contraindication' mean in the context of Acmic?

A contraindication is a specific condition or circumstance where official regulatory guidance prohibits use because the potential risks outweigh the benefits. For Acmic, this includes a known hypersensitivity or allergy to any component, and specific underlying conditions like Leber’s Disease.

Q: Is Acmic considered a controlled substance?

No. Acmic is classified as a B-complex vitamin supplement, often available Over-The-Counter (OTC), and is not designated as a controlled substance by regulatory agencies, meaning it has no known potential for abuse or dependence.

Q: Can Acmic be taken with supplements like vitamins or herbs?

Official regulatory guidance includes information encouraging patients to disclose the use of all products to their healthcare provider. This precaution is noted because certain components may interfere with absorption or metabolic effects of other supplements.

Q: How is Acmic different from an antibiotic?

Acmic is classified in the pharmacological class of B-complex vitamin supplements, functioning as a nutritional agent. This is fundamentally different from an antibiotic, which is a type of medicine used specifically to treat bacterial infections.

Q: What is the biggest misunderstanding about Acmic that people talk about?

A key regulatory warning focuses on the Folic Acid (B9) component, which may mask the hematological signs of an underlying B12 deficiency. While it may correct the blood cell problems associated with B12 deficiency, it can allow potential nerve damage to progress undetected, which is why official labeling includes this explicit precaution.

Q: If I am taking Acmic, should I limit alcohol consumption?

Official regulatory documentation notes that alcohol consumption can decrease the gastrointestinal absorption of certain B-complex vitamins (B1 and B6) and contribute to Folic Acid deficiency. This factual statement regarding reduced nutrient availability is provided for user awareness.

Q: Why is it important to know about Acmic's interactions?

Official documentation concerning drug interactions is important because other substances, whether medicines, foods, or supplements, can interfere with how Acmic is processed by the body. This interference could potentially reduce Acmic’s intended effect or increase the risk of certain side effects from either Acmic or the co-administered product.

Q: What is the difference between a common side effect and a serious side effect of Acmic?

In official labeling, common reactions (e.g., nausea, mild rash) are those frequently observed in studies, often being mild and temporary. Serious adverse reactions (e.g., Anaphylaxis, Peripheral Sensory Neuropathy) are rare events which are listed as serious adverse events in regulatory documents.

Q: Does Acmic interact with birth control pills?

Official regulatory documents for Acmic and its B-complex components typically do not list an interaction with hormonal birth control pills. Official documentation encourages disclosure of all medications to a healthcare provider.

Q: What does the term 'mechanism of action' mean for Acmic in simple words?

The mechanism of action describes how Acmic works at the cellular level. In simple terms, it means the drug provides essential B-vitamins that act as coenzymes (helper molecules) to enable the body’s cells to perform fundamental metabolic processes, such as generating new DNA and maintaining the health of nerve structures.

Q: Does Acmic have a 'black box warning' in the US?

A B-complex vitamin supplement like Acmic typically does not carry a Boxed Warning (colloquially called a 'black box warning'). This type of warning is reserved for certain FDA-approved prescription drugs associated with a severe, life-threatening risk that warrants prominent display on the drug label.

Q: Is Acmic safe to use before driving or operating machinery?

Regulatory information for B-complex vitamins does not typically list warnings about operating machinery or driving. However, the labeling notes rare adverse effects like dizziness or fatigue that could potentially impair a person's ability to perform such tasks.

Q: Is Acmic habit-forming or addictive?

No. Acmic is classified as a vitamin supplement and is not associated with a risk of abuse or dependence. Regulatory agencies do not classify it as a controlled substance.

Q: Is it normal to feel a change in appetite while using Acmic?

A change in appetite is not typically listed as a common or frequent side effect in official Acmic labeling. While other gastrointestinal issues like nausea and diarrhea are listed as common reactions, appetite change is not explicitly mentioned.

Q: Can Acmic be cut in half or crushed?

Regulatory labeling for the oral tablet form does not usually authorize or provide instructions for cutting or crushing the tablet. Unless the tablet is scored (has a dividing line), it is generally intended to be swallowed whole to ensure the drug’s intended release profile is maintained.

Q: What if I experience a rare side effect of Acmic?

Regulatory documents state that if any signs of a serious adverse reaction (such as an allergic reaction) occur, or if any symptom is severe or persistent, official regulatory documents indicate that a healthcare professional is to be contacted immediately. This allows for any unexpected or rare effects to be reported and addressed.

How should Acmic be stored and disposed of?

How to Store and Dispose of Acmic?

The storage and disposal of Acmic tablets must adhere strictly to regulatory guidelines to ensure product stability and household safety.


Mandatory Storage Conditions

Acmic must be stored in a clean and dry place at room temperature. It is mandatory to keep the product in its original container and ensure it is protected from moisture, excessive heat, and direct sunlight to maintain the stability of the B-complex components.

Household Safety and Disposal Rules

For safety, the medicine must be stored out of the sight and reach of children and pets.

Disposal must follow pharmaceutical waste guidelines: do not flush the tablets down the toilet or pour them down any drain. The recommended method for discarding unused or expired Acmic is to return it to an official drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acmic found in:

A-Z Index: